- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07938515
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations for DA-302168S in subjects with renal impairment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: xiaolong qin
- Número de telefone: 18781997925
- E-mail: qinxiaolong.cn@outlook.com
Locais de estudo
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recrutamento
- The Second Affiliated Hospital of Soochow University
-
Contato:
- xiaolong qin
- Número de telefone: 18781997925
- E-mail: qinxiaolong.cn@outlook.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18-65 years inclusive at ICF signing, male or female; age matching (±10 years) between normal and renal impairment groups, with sex matching as far as possible (±1 participant per sex).
- Weight and BMI at screening: male ≥50.0 kg, female ≥45.0 kg; BMI 19.0-30.0 kg/m² inclusive; weight matching (±10 kg) between normal and renal impairment groups.
- Fertile female or male participants must agree to use reliable contraception for themselves and their partners during the study and for 90 days after dosing (see Appendix 3), and must not donate sperm or oocytes/eggs for assisted reproduction.
- Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with protocol requirements and complete the related procedures.
Exclusion Criteria:
- History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or screening serum calcitonin ≥50 ng/L.
- History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
- History of acute gallbladder disease within 3 months before ICF signing.
- Any malignancy within 5 years before ICF signing (except curatively treated basal cell carcinoma considered cured).
- History of severe cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, endocrine, or other systemic disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
- Investigator-judged dysphagia at screening, or conditions possibly affecting drug absorption, distribution, metabolism, or excretion (e.g., active inflammatory bowel disease, gastrectomy, any intestinal resection).
- Severe hypoglycemia within 3 months before screening.
- Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of investigational drug <5 half-lives before screening.
- History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance/allergy to GLP-1 receptor agonists.
- Major surgery within 1 year before screening [major surgery defined as surgery on intracranial, thoracic, abdominal, pelvic, or limb organs causing major tissue trauma and requiring prolonged recovery (e.g., organ transplantation, cardiac surgery, joint replacement)], or planned surgery during the study.
- Blood donation or massive blood loss (≥400 mL) within 3 months before screening or between screening and first dose, or planned blood donation during the study.
- History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDMA, cocaine) or positive baseline urine drug test.
- Smoking >5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, or inability to abstain during the study.
- History of alcohol abuse within 1 year before screening (male >14 standard units/week, female >7 standard units/week; 1 standard unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive baseline breath/blood alcohol test.
- Special dietary requirements and inability to accept a standardized diet.
- Consumption of grapefruit-rich beverages or foods within 7 days before first dose, or unwillingness to stop during the study.
- Vaccination within 30 days before dosing, or planned vaccination within 30 days after dosing.
- Inability to avoid strenuous exercise or other behaviors possibly affecting PK parameters from 48 h before dosing through the study.
- History of needle/blood phobia, difficult blood collection, or intolerance to venipuncture.
- Pregnant or lactating women.
- Participant is an investigator or other related research staff for this project.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group A
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
Experimental: Group B
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
Comparador de Placebo: Group C
Subjects with normal renal function matched to renal impairment subjects |
Small molecule GLP-1RA tablet |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Peak Plasma Concentration (Cmax) of DA-302168S
Prazo: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
|
Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168S
Prazo: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026-CP-DA168-14
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .